BREAKING: Gold Prices, Stocks Continue To Slide With third-quarter earnings on tap for Oct. 28, Wall Street has genomics and rare-disease diagnostics leader GeneDx (WGS) squarely on its radar. Here are four reasons investors should take a close look at GeneDx stock. The U.S. Food and Drug Administration on Monday granted Breakthrough Device Designation for the company's ExomeDx and GenomeDx testing. The tests aim to identify causes of life-threatening diseases or genetic disorders, helping to diagnose sympt ...